HGF and neoplasm: However, the mean percentage (27%) of tumor volume reduction in the HGF-treated tumors was obviously less than that of the control (62.7%), HGF+PI3K inhibitor (48.3%) and HGF+GRP78 inhibitor-treated tumors (45.8%) (Fig 5B).